A Multiparametric Approach Based on NT-proBNP, ST2, and Galectin3 for Stratifying One Year Prognosis of Chronic Heart Failure Outpatients

Grande, Dario; Leone, Marta; Rizzo, Caterina; Terlizzese, Paola; Parisi, G.; Gioia, Michele De; Leopizzi, Tiziana; Segreto, Antonio; Guida, Piero; Romito, Roberta; Ciccone, Marco Matteo; Serio, Francesca Di; Iacoviello, Massimo

doi:10.3390/jcdd4030009

Cited by 19 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Beyond assessment of natriuretic peptides, other biomarkers of mechanisms contributing to the pathophysiology of HF, such as inflammation (GDF‐15 and sST2), LV hypertrophy (FGF‐23), and myocardial necrosis (hsTnT), could add important prognostic information and identify patients at higher risk of events 44–47 . Studies have already demonstrated the superiority of different biomarkers combinations, including NT‐proBNP, sST2, and Galectin‐3 for risk stratification of chronic HF patients 48,49 . In 2015, we showed the additive value of FGF‐23, Galectin 3, and sST2 compared with NT‐proBNP for prediction of cardiovascular death in HFrEF 50 .…”

Section: Discussionmentioning

confidence: 79%

“…[44][45][46][47] Studies have already demonstrated the superiority of different biomarkers combinations, including NT-proBNP, sST2, and Galectin-3 for risk stratification of chronic HF patients. 48,49 In 2015, we showed the additive value of FGF-23, Galectin 3, and sST2 compared with NT-proBNP for prediction of cardiovascular death in HFrEF. 50 However, in the specific CORONA-HF population, a multimarker approach using a panel of 20 inflammatory and extracellular matrix biomarkers (including sST2 and galectin-3) was of limited clinical value for identifying the risk of adverse outcomes.…”

Section: Prognostic and Risk Stratificationmentioning

confidence: 96%

See 1 more Smart Citation

Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction

et al. 2020

View full text Add to dashboard Cite

Aims Besides regulating calcium-phosphate metabolism, fibroblast growth factor 23 (FGF-23) has been associated with incident heart failure (HF) and left ventricular hypertrophy. However, data about FGF-23 in HF and preserved ejection fraction (HFpEF) remain limited. The aim of this study was to assess the association between FGF-23 levels, clinical and imaging characteristics, particularly diffuse myocardial fibrosis, and prognosis in HFpEF patients. Methods and results We prospectively included 143 consecutive HFpEF patients (78 ± 8 years, 61% female patients) and 31 controls of similar age and gender (75 ± 6 years, 61% female patients). All subjects underwent a complete two-dimensional echocardiography and cardiac magnetic resonance with extracellular volume (ECV) assessment by T1 mapping. FGF-23 was measured at baseline. Among the patients, differences in clinical and imaging characteristics across tertiles of FGF-23 levels were analysed with a trend test across the ordered groups. Patients were followed over time for a primary endpoint of all-cause mortality and first HF hospitalization and a secondary endpoint of all-cause mortality. Median FGF-23 was significantly higher in HFpEF patients compared with controls of similar age and gender (247 [115; 548] RU/mL vs. 61 [51; 68] RU/mL, P < 0.001). Among HFpEF patients, higher FGF-23 levels were associated with female sex, higher incidence of atrial fibrillation, lower haemoglobin, worse renal function, and higher N terminal pro brain natriuretic peptide levels (P for trend < 0.05 for all). Regarding imaging characteristics, patients with higher FGF-23 levels had greater left atrial volumes, worse right ventricular systolic function, and more fibrosis estimated by ECV (P for trend < 0.05 for all). FGF-23 was moderately correlated with ECV (r = 0.46, P < 0.001). Over a mean follow-up of 30 ± 8 months, 43 patients (31%) died and 69 patients (49%) were hospitalized for HF. A total of 87 patients (62%) reached the primary composite endpoint of all-cause mortality and/or first HF hospitalization. In multivariate Cox regression analysis for the primary endpoint, FGF-23 (HR: 3.44 [2.01; 5.90], P < 0.001) and E wave velocities (HR: 1.01 [1.00; 1.02], P = 0.034) were independent predictors of the primary composite endpoint. In multivariate Cox regression analysis for the secondary endpoint, ferritin (HR: 1.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Prognostic and Risk Stratificationmentioning

confidence: 96%

Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Other large-scale studies had analyzed the 5,10,27,33 potential of ST2 for predicting prognosis. Nowadays, ST2 is recognized as a marker to support risk stratification and prognosis of heart failure 1,34…”

Section: Resultsmentioning

confidence: 99%

Comparison of Concentration Difference between ST2 and NT-Pro BNP Before and After Ace-Inhibitors in NYHA III-IV Hearts Failure Patients

Maskito¹,

Anniwati²,

Aminuddin³

2019

Indonesian J. Clin. Pathol. Med. Lab.

View full text Add to dashboard Cite

Background: The American Heart Association (2016) stated that at the age of forty the risk of developing heart failure is one in five. Medication is based on clinical signs and symptoms that are often late. Early cardiac markers are required to guide therapy. This study compared the difference between ST2 and NT-ProBNP concentrations before and after ACE inhibitors (ACE-I) in NYHA III-IV heart failure patients.Method: This was a randomized prospective observational study without controls. The respondents were males or females, 21-75 y.o in NYHA III-IV heart failure patients. Twenty-five respondents were appropriate to inclusion criteria. The ST2 was measured by Quantikine®ST2/IL-33R quantitative sandwich ELISA immunoassay while NT-proBNP was measured by Immulite Turbo® 1000.Result: Majority of respondents were males (60%) and had comorbidities(60,7%), consisting of NYHA Class III(36%) and IV(64%). Coronary artery disease and valvular heart disease (40%,36% respectively). Length of stay was 6.4±3.4days. The concentration difference of ST2 and NT-proBNP before and after ACE-I were both significant, however, NT-proBNP was more significant (p=0,001 vs p=0,023). NYHA at admission influenced ST2 difference but not NT-proBNP. NT-proBNP concentration correlated to length of stay while ST2 was not. ST2 had negative correlation with age, no correlation to GFR and weight. NT-proBNP was correlated to weight, negatively correlated to GFR, not correlated to age. ACE-I subtypes difference did not affect the study result.Conclusion: NT-proBNP was a better heart failure cardiac marker than ST2 due to its ability in diagnosis, prognosis and showing more significant difference after ACE-I administration.

show abstract

“…ST2, галектин-3 и NT-proBNP представляют собой панель биомаркеров фиброза миокарда с частично перекрывающимися патофизиологическими механизмами действия. Повышение уровней NT-proBNP, galectin-3 и ST2 в сыворотке крови у амбулаторных больных с хронической сердечной недостаточностью в стабильном клиническом состоянии идентифицирует пациентов с самым высоким риском прогрессирования сердечной недостаточности [49]. Концентрации циркулирующего sST2 коррелируют с более тяжелым фенотипом заболевания, включая неблагоприятное ремоделирование и фиброз, сердечную дисфункцию, нарушение гемодинамики и более высокий риск прогрессирования ССЗ.…”

Section: биомаркеры фиброзаunclassified

“…Таким образом, ранний каротидный рестеноз (>50%) после КЭА с высокой вероятностью встречается у пациентов, гомозиготных по нормальному аллелю MBL2, и ассоциирован с выраженным повышением сывороточных уровней VEGF и/или PDGF после операции [122]. высокий риск иБС [113] NT-proBNP сердечная недостаточность с редуцированной фракцией выброса [49], [81], [111] сердечная недостаточность с сохранененной фракцией выброса…”

Section: биомаркеры рестенозаunclassified

Biomarkers of Cardiovascular Disease

Scherbak

Григорьевич²,

Лисовец

et al. 2019

Physical and rehabilitation medicine, medical rehabilitation

View full text Add to dashboard Cite

Inflammation, cardiac remodeling, and fibrosis are potentially important pathways in the pathogenesis of cardiovascular diseases. Complications of atherosclerosis are one of the leading causes of death in the world. Effective prevention of cardiovascular disease by adequate control of major cardiovascular risk factors can provide substantial public health gains. However, detection and control of major cardiovascular risk factors continues to be a major challenge because of poor awareness of an individual's status. A solution to this problem is important for an early identification and appropriate correction of cardiovascular risk factors. Atherosclerotic plaque development is regarded as a chronic inflammatory process which involves interactions between lipids, immune cells and the artery wall. Numerous evidence suggests that inflammation plays an important role in all stages of the atherosclerotic process. The study of associations of inflammatory biomarkers has led to the idea that the panel of inflammatory biomarkers can identify people at high risk of developing atherosclerosis and cardiovascular diseases when anti-inflammatory treatment can prevent further unfavorable events. The most common forms of cardiovascular diseases are caused by atherosclerosis, the progressive thinning of blood vessels due to accumulation of lipids within the arterial wall. While many factors are known to influence the development and progression of atherosclerosis, circulating levels of cholesterol and lipoprotein complexes are the most important risk factors and mediators of atherosclerotic disease. Key regulators of lipid metabolism and/or the development of atherosclerosis have diagnostic, prognostic and therapeutic potential for cardiovascular diseases.

show abstract

A Multiparametric Approach Based on NT-proBNP, ST2, and Galectin3 for Stratifying One Year Prognosis of Chronic Heart Failure Outpatients

Cited by 19 publications

References 37 publications

Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction

Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction

Comparison of Concentration Difference between ST2 and NT-Pro BNP Before and After Ace-Inhibitors in NYHA III-IV Hearts Failure Patients

Biomarkers of Cardiovascular Disease

Contact Info

Product

Resources

About